• 1-800-526-8630U.S. (TOLL FREE)
  • 1-917-300-0470EAST COAST U.S.
  • +353-1-416-8900REST OF WORLD

Significant Pharmaceuticals Reported in US Patents

  • ID: 1763363
  • May 2007
  • Region: United States
  • 700 Pages
  • Elsevier Science and Technology

This book identifies the next generation of pharmaceuticals reported in US Patents. This "hands-on" title provides explicit laboratory methods for preparing the most recent and effective medications. Each entry documents the biological testing protocols used to evaluate a drug and the significance of the current treatment agent over previous methods. Pharmaceuticals are included in this review only if at least two of the following criteria were met: Effectiveness in treating an illness, Innovative, ease of preparation, synergy with existing Medications.
Pharmaceuticals are reported for 27 separate classes of illness, including;
AIDS, Alzheimer's Disease, Cardiovascular Disorders, Diabetes, Epilepsy, Hepatitis C, Osteoporosis, Obesity and Sleep Disorders.
Significant Pharmaceuticals Reported in US Patents has been designed to be used as both a reference and synthetic guide for pharmaceutical, medicinal and organic chemists and graduate students.
Researchers working in other areas will also find the information valuable as in many instances intermediates or the next generation pharmaceutical are readily convertible into other industrial products including: anti-oxidants, chemical additives, herbicides, polymer precursors, water purification agents. Clear structural depictions of reagents and chemical transformations have been supplied to permit the identification of other future applications.

Identifies next generation pharmaceuticals
Provides practical preparation methods for each active agent and derivatives
Documents the analytical characterization and biological testing results of active agents

Note: Product cover images may vary from those shown

Acquired Immune Deficiency Syndrome
Addiction Disorders
Alzheimer's Disease
Antibacterial Agents
Anti-inflammatory Agents
Autoimmune Disorders
Cardiovascular Disorders
Gastrointestional Disorders
Hepatitis C
Hormonal Disorders
Improved Synthetic Methods
Irritable Bowel Syndrome
Migraine Headaches
Proliferative Disorders
Skin Disorders
Sleep Disorders
Thyroid Disorders

Note: Product cover images may vary from those shown

DeRosa, Thomas F.

Note: Product cover images may vary from those shown
Note: Product cover images may vary from those shown


Our Clients

Invista Sigma-Aldrich Corporation BASF SE Clariant International Ltd. Bayer AG Arkema Group